Alt iLive-innhold blir gjennomgått med medisin eller faktisk kontrollert for å sikre så mye faktuell nøyaktighet som mulig.
Vi har strenge retningslinjer for innkjøp og kun kobling til anerkjente medieområder, akademiske forskningsinstitusjoner og, når det er mulig, medisinsk peer-evaluerte studier. Merk at tallene i parenteser ([1], [2], etc.) er klikkbare koblinger til disse studiene.
Hvis du føler at noe av innholdet vårt er unøyaktig, utdatert eller ellers tvilsomt, velg det og trykk Ctrl + Enter.
Cyclin D1 expression may be a biomarker for penile cancer
Sist anmeldt: 14.06.2024
A new scientific article entitled "Cyclin D1 Expression in Penile Cancer" has been published in Oncotarget.
In this new study, researchers analyzed the expression profile of cyclin D1 in patients with penile cancer (PC) and identified possible correlations with clinical and histopathological features.
"However, regarding HCC, there are few studies evaluating the role of cyclin D1, highlighting the need for initiatives aimed at studying its actual role in the pathophysiology of this disease. Therefore, the present study aimed to characterize the expression of cyclin D1 in patients with HCC and identify possible correlations with clinical and histopathological features of the disease," the researchers write.
A total of 100 patients diagnosed with cancer and treated at two reference hospitals in São Luis, Maranhão, Brazil, between 2013 and 2017 were studied. A review of clinical, epidemiological and histopathological data was performed, human papillomavirus (HPV) DNA was detected using polymerase chain reaction (PCR), and cyclin D1 expression analysis was performed using immunohistochemical methods.
Cyclin D1 protein expression in immunohistochemical analysis of histological sections. Source: Oncotarget (2024). DOI: 10.18632/oncotarget.28584
Data showed that lack of cyclin D1 expression was significantly associated with HPV-positive histological subtypes (p = 0.001), while its expression was associated with high-grade tumors (p = 0.014), histological subtype (p = 0.001), the presence of sarcomatoid transformation (p = 0.04) and perineural invasion (p = 0.023). Patients with cyclin D1 expression had lower disease-free survival compared with the cyclin D1-negative group, although the difference was not statistically significant.
“The results suggest that cyclin D1 may be a potential biomarker for cancer, particularly for worse prognosis,” the researchers conclude.